Enzyme Jelly OEM Audit Follow-Up: Grading Findings, Root Cause and Closing CAPA with Evidence
For an enzyme jelly programme, a brand team arrives, audits the plant and leaves behind a list of findings. In modern contract manufacturing that is normal rather than alarming. What determines the quality of the partnership is not how many findings appear on the report but how quickly and how thoroughly they are closed. Many manufacturers treat corrective action as "fix that one item", and the same finding reappears verbatim at the next audit. The disciplined approach runs the full sequence: grade the finding, find the root cause, correct, prevent, verify, standardise. Whether that sequence was genuinely followed is usually visible in the wording of the closing report.
1. Grading: deciding how much resource to commit
Findings are not equivalent, and the first step is to grade them. Major or critical findings are those affecting product safety or legality directly, or representing systemic failure: a critical control point out of control, falsified batch records, raw material that cannot be traced. Minor findings are isolated execution lapses that do not directly affect safety: an incomplete record, a piece of equipment past its calibration date. Observations or recommendations are improvement opportunities rather than non-conformities. The grade sets both the resource and the deadline: critical findings normally demand immediate containment plus root cause analysis and correction within a defined number of days, while minors can be scheduled into a monthly improvement plan. When reviewing a closing report, the first thing to check is whether the grading itself is credible - classifying everything as minor is itself a warning sign.
2. Root cause: stop before "operator error"
Root cause analysis is where corrective action most often becomes theatre. The standard failure is writing "operator carelessness" or "insufficient training" as the cause: those are symptoms, not causes. The useful question is why a careful operator would slip. Plausible answers include unclear work instructions, a workstation layout that makes the correct action awkward, handover time pressure, or the absence of any independent check. Two tools do most of the work: repeated questioning, asking why five times in succession until the answer reaches something the organisation can actually change; and a structured sweep across the six categories of man, machine, material, method, environment and measurement. The test for a genuine root cause is simple - does the corrective action point at a system element that can be changed? If the only action is "retrain the operator", the root cause was never found.
3. Correction, corrective action and prevention are three different things
Confusing these three is the most common structural error in a CAPA record. Correction deals with the problem that has already occurred: quarantine the suspect batch, rework, recall. Corrective action addresses the root cause so it does not happen again: revise the work instruction, add an in-process check, modify the equipment. Preventive action addresses potential risk so the same class of problem does not emerge elsewhere: extend the improvement to comparable processes, update the risk assessment. A complete plan has all three - what happens to this batch, how the cause is eliminated, and how comparable risk is covered. Doing only the first of the three simply pushes the problem into next quarter.
4. Verification: no evidence, no closure
Once actions are complete, effectiveness has to be verified, and this is the step most frequently skipped. Verification runs in three layers. Completion: confirm the change actually happened - the document was issued, the equipment was modified, the training was delivered. Effectiveness: confirm the problem genuinely stopped, usually by tracking several batches of data and comparing against the pre-correction baseline. Risk confirmation: confirm the change did not introduce a new hazard, for example whether a check removed to improve throughput has created a new gap in detection. Each layer needs objective evidence: revised document numbers and versions, training attendance and assessment records, consecutive batch test data, and a signed verification conclusion. "Completed" without evidence reads as not done at the next audit.
5. Standardisation and horizontal deployment
A correction at one point has limited value. What builds system capability is deploying it sideways and locking it in. Horizontal deployment means extending an improvement to every comparable process and line: if a mistake-proofing device was fitted to one depositor, assess whether the others need it too. Standardisation means embedding what was validated into the management system - update the work instruction, revise the process control parameters, add the item to the internal audit checklist, and write it into operator training material. Only at that point does the audit investment convert into improved capability. Correspondingly, a closing report with no document number changes and no training records usually means the correction stayed at the level of the individual case.
6. How a brand should read a CAPA report
For a brand, the audit and the closing report are the most informative material available when qualifying a manufacturer. Four observations are worth making. Is the grading objective, or have critical findings been softened? Does the root cause reach system level, or does it stop at retraining? Does the plan contain correction, corrective action and prevention, or only the first? And is effectiveness supported by objective evidence and follow-up batch data? Timeliness matters too - whether promised closure dates were met and whether overruns were explained. The value of a manufacturer that handles corrective action properly is not a clean first audit. It is the proven ability to close what was found and not repeat it at the next one.
Related Products
Extra Strength Orange Enzyme Jelly with Prebiotics | Fruit-Flavored Cup Jelly Private Label OEM Manufacturer | Collagen Fruit & Vegetable Enzyme Jelly with Prebiotics | Custom Extra Strength Jelly OEM Factory
About Guangzhou Mesen Health Biotechnology Co., Ltd
Guangzhou Mesen Health Biotechnology Co., Ltd is located in the Huashan Science and Technology Park, Huadu District, Guangzhou. The company has focused on OEM and ODM services for the big health industry for nearly 20 years, operating dedicated research, production, sales and management centres, and maintaining long-term strategic partnerships with well-known Chinese medicine colleges and research institutions. Capabilities span pressed candy, gummies, capsules, solid beverages, herbal teas, plant beverages, protein powders, dietary supplements and enzyme jelly - from formulation development through contract manufacturing. For details on minimum order quantities, sampling lead times and quotations, see our manufacturing advantages and product range, or contact us for a tailored proposal.
Further Reading
